Emerging evidence suggests that STAT3 activation can induce epithelial-mesenchymal transition and consequently propagate cancer stem cells (CSCs) that have been described to be responsible for HER2-targeting drug resistance and ultimate tumor recurrence in breast and gastric cancers [22-25]. This evidence concerns the gene ERBB2 and gastric cancer.